GRM3 and central nervous system cancer: mGluR3 is consistently expressed in human glioblastomas or glioma cell lines, and its antagonist LY341493 reduces cell growth with the inhibition of the MAP kinase and PI3K signaling pathways (D'Onofrio et al., 2003; Arcella et al., 2005).